Knopp begins phase 2 trial for oral dexpramipexole in eosinophilic asthma
Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020.
Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.
Rearranged during transfection (RET) is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET fusions are implicated in several cancers including
“We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis